Clementia Pharmaceuticals

Ipsen doubles down on rare bone disease
EP Vantage
Wed, 10/16/19 - 07:18 pm
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
Mon, 02/25/19 - 10:04 am
M&A
Ipsen
Clementia Pharmaceuticals
Rare Diseases
With clear FDA path, Clementia raises $70.2M
BioCentury
Wed, 10/31/18 - 09:52 am
Clementia Pharmaceuticals
fibrodysplasia ossificans progressiva
palovarotene
Clementia jumps on NDA plans for unmet rare bone disease
BioCentury
Wed, 10/24/18 - 11:44 pm
Clementia Pharmaceuticals
FOP
palovarotene
fibrodysplasia